Abstract
Existing treatments of traumatic brain injury (TBI) have failed to reverse tremendous losses in productivity, independence and overall quality of life among TBI victims and therefore, cannot be viewed as sufficient. Although there is no shortage of promising basic concepts that may translate to efficacious therapies after TBI, the accumulated knowledge has yet to deliver treatments that adequately meet clinical and social demands. In this article, we discuss novel concepts, recent advances and accompanying challenges in developing cholinergic and related therapies after TBI.
Keywords: Trauma, brain, injury, cholinergic, nicotinic, acetylcholine, vagus, vagal, stimulation, inflammatory, immune.
Current Pharmaceutical Design
Title:The Cholinergic Potential, the Vagus Nerve and Challenges in Treatment of Traumatic Brain Injury
Volume: 22 Issue: 14
Author(s): Victor V. Uteshev, Olli Tenovuo and Nikhil Gaidhani
Affiliation:
Keywords: Trauma, brain, injury, cholinergic, nicotinic, acetylcholine, vagus, vagal, stimulation, inflammatory, immune.
Abstract: Existing treatments of traumatic brain injury (TBI) have failed to reverse tremendous losses in productivity, independence and overall quality of life among TBI victims and therefore, cannot be viewed as sufficient. Although there is no shortage of promising basic concepts that may translate to efficacious therapies after TBI, the accumulated knowledge has yet to deliver treatments that adequately meet clinical and social demands. In this article, we discuss novel concepts, recent advances and accompanying challenges in developing cholinergic and related therapies after TBI.
Export Options
About this article
Cite this article as:
Uteshev V. Victor, Tenovuo Olli and Gaidhani Nikhil, The Cholinergic Potential, the Vagus Nerve and Challenges in Treatment of Traumatic Brain Injury, Current Pharmaceutical Design 2016; 22 (14) . https://dx.doi.org/10.2174/1381612822666160127111630
DOI https://dx.doi.org/10.2174/1381612822666160127111630 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Myogenic Tone as a Therapeutic Target for Ischemic Stroke
Current Vascular Pharmacology RNase Therapy Assessed by Magnetic Resonance Imaging Reduces Cerebral Edema and Infarction Size in Acute Stroke
Current Neurovascular Research Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Current Pharmaceutical Design Update on the Role of Neutrophils in Atherosclerotic Plaque Vulnerability
Current Drug Targets Synaptic and Extrasynaptic Glutamate Signaling in Ischemic Stroke
Current Medicinal Chemistry A Path to Development or Demise ?
Current Neurovascular Research Gadolinium-based Imaging Contrast Agents
Current Medical Imaging Neuritin, A Neurotrophic Factor in Nervous System Physiology
Current Medicinal Chemistry The Role of Antihistamines in the Management of Allergic Rhinitis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Current Issues in Intravenous Fluid Use in Hospitalized Children
Reviews on Recent Clinical Trials Neuroprotection of Dietary Virgin Olive Oil on Brain Lipidomics During Stroke
Current Neurovascular Research Visualising Neuroinflammation in Post-Stroke Patients: A Comparative PET Study with the TSPO Molecular Imaging Biomarkers [<sup>11</sup>C]PK11195 and [<sup>11</sup>C]vinpocetine
Current Radiopharmaceuticals Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Current Drug Targets The Molecular Basis of the Interplay between Endothelin-1 and Nitric Oxide and its Relevance for Atherosclerosis and Arterial and Pulmonary Hypertension
Vascular Disease Prevention (Discontinued) Tandem Repeat Peptide Strategy for the Design of Neurotrophic Factor Mimetics
CNS & Neurological Disorders - Drug Targets Effects of LPA and S1P on the Nervous System and Implications for Their Involvement in Disease
Current Drug Targets Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the Art
Current Topics in Medicinal Chemistry The Role of VE-cadherin in Blood-brain Barrier Integrity Under Central Nervous System Pathological Conditions
Current Neuropharmacology The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia
Current Neurovascular Research Herb-Drug Interactions and Mechanistic and Clinical Considerations
Current Drug Metabolism